Rezelj, V.V.; Paddenburg, F.; Diegbe, M.E.; Nangosyah, J.; Reisinger, E.C.; Hu, W.; Truyers, C.; Scheper, G.; Le Gars, M.; Hendriks, J.;
et al. Safety and Humoral Immunogenicity of Different Dose Levels of Ad26.COV2.S as a 2-Dose Regimen in COVID-19 Vaccine-Naïve Healthy Adults: A Phase 3 Randomized Clinical Trial. Vaccines 2024, 12, 1136.
https://doi.org/10.3390/vaccines12101136
AMA Style
Rezelj VV, Paddenburg F, Diegbe ME, Nangosyah J, Reisinger EC, Hu W, Truyers C, Scheper G, Le Gars M, Hendriks J,
et al. Safety and Humoral Immunogenicity of Different Dose Levels of Ad26.COV2.S as a 2-Dose Regimen in COVID-19 Vaccine-Naïve Healthy Adults: A Phase 3 Randomized Clinical Trial. Vaccines. 2024; 12(10):1136.
https://doi.org/10.3390/vaccines12101136
Chicago/Turabian Style
Rezelj, Veronica V., Fred Paddenburg, Marie Enajite Diegbe, Julius Nangosyah, Emil C. Reisinger, Weihong Hu, Carla Truyers, Gert Scheper, Mathieu Le Gars, Jenny Hendriks,
and et al. 2024. "Safety and Humoral Immunogenicity of Different Dose Levels of Ad26.COV2.S as a 2-Dose Regimen in COVID-19 Vaccine-Naïve Healthy Adults: A Phase 3 Randomized Clinical Trial" Vaccines 12, no. 10: 1136.
https://doi.org/10.3390/vaccines12101136
APA Style
Rezelj, V. V., Paddenburg, F., Diegbe, M. E., Nangosyah, J., Reisinger, E. C., Hu, W., Truyers, C., Scheper, G., Le Gars, M., Hendriks, J., Struyf, F., Douoguih, M., Schuitemaker, H., & Ruiz-Guiñazú, J.
(2024). Safety and Humoral Immunogenicity of Different Dose Levels of Ad26.COV2.S as a 2-Dose Regimen in COVID-19 Vaccine-Naïve Healthy Adults: A Phase 3 Randomized Clinical Trial. Vaccines, 12(10), 1136.
https://doi.org/10.3390/vaccines12101136
